Yes we are, not buy into this bs that the conversion will be completed by Sept. patients will drop the 40mg a week dose once insurance will no longer cover.
Truth. The ACA has cost people millions more in their insurance and all managed care companies are cutting cost to the bone, no way anyone is going to pay more when a generic is available much cheaper. No new products are going to replace the Copaxone revenue stream. Time is very limited.
The fact your just now figuring this out is scary. What exactly did you expect to happen? Take a wild guess where the remaining "cost savings" to complete our reshape initiative will come from....
Assume continued viability for another 6 months after first generic due to exclusivity, then the floor will open up with multi-source.
Even Teva knows the generic in September is going to erode Copaxones market. All these conversions are great but generics will still take the market. http://www.fiercepharma.com/story/teva-takes-another-swing-generic-copaxone-new-fda-petition/2015-04-02?utm_medium=rss&utm_source=feedly&utm_campaign=rss
This company is a law firm. It costs less to sue and prevent than it does to research and develop. No worries.
I hate that this will effect individuals, but glad because your company deserves this! Teva has been in the business of challenging patents before they are up. I know of multiple sales forces that have been Sh*t canned because of Teva's "early generics". Karma......
Looks like the FDA has given Teva a clear message to its delay arguments. Sandoz will launch using Novartis Gilenya commercial team to emphasize the point.
